Provention Bio, Inc. (PRVB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Provention Bio, Inc. (PRVB) trades at $24.98 with AI Score 68/100 (Buy). Provention Bio, Inc. is a clinical-stage biopharmaceutical company focused on intercepting and preventing immune-mediated diseases, particularly type 1 diabetes. Market cap: $2.38B, Sector: Healthcare.
Last analyzed: Feb 8, 2026Provention Bio, Inc. (PRVB) Healthcare & Pipeline Overview
Provention Bio pioneers immune-mediated disease interception with its lead candidate teplizumab targeting type 1 diabetes, offering a notable research candidate in a high-growth biotech sector focused on preventative therapies and strategic partnerships for expanded market reach and innovative solutions.
Investment Thesis
Provention Bio presents a notable research candidate due to its focus on preventative therapies for immune-mediated diseases, particularly type 1 diabetes (T1D). The potential approval and commercialization of teplizumab, its lead candidate, could generate significant revenue, given the unmet need for T1D interception. The company's strategic collaborations with Amgen and Hangzhou Zhongmei Huadong Pharmaceutical further de-risk development and expand market reach. With a gross margin of 96.0%, successful commercialization could lead to substantial profitability. Key value drivers include positive clinical trial outcomes for its pipeline products and successful market penetration of teplizumab. Upcoming catalysts include continued clinical trial progress and potential regulatory approvals, making PRVB an attractive investment in the biotechnology sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $2.38B reflects investor confidence in Provention Bio's pipeline and potential for future growth.
- Gross Margin of 96.0% indicates strong pricing power and efficient cost management upon commercialization.
- PRV-031 (teplizumab) in Phase III clinical trial represents a significant near-term value driver with potential for regulatory approval.
- Strategic collaborations with Amgen and Hangzhou Zhongmei Huadong Pharmaceutical enhance development and commercialization capabilities.
- Focus on preventative therapies for immune-mediated diseases positions Provention Bio in a high-growth segment of the biotechnology industry.
Competitors & Peers
Strengths
- Focus on preventative therapies for immune-mediated diseases.
- Lead product candidate (teplizumab) in late-stage clinical development.
- Strategic collaborations with established pharmaceutical companies.
- Strong gross margin potential upon commercialization.
Weaknesses
- Clinical-stage company with no currently marketed products.
- High operating expenses due to ongoing clinical trials.
- Reliance on regulatory approvals for product commercialization.
- Negative profit margin.
Catalysts
- Ongoing: Continued clinical trial progress for PRV-031 (teplizumab) in T1D interception.
- Upcoming: Potential regulatory approval of teplizumab by the FDA.
- Ongoing: Advancement of PRV-3279 for the treatment of lupus through clinical trials.
- Ongoing: Development of PRV-101 (CVB vaccine) and progression through clinical trials.
Risks
- Potential: Failure to obtain regulatory approvals for teplizumab or other product candidates.
- Potential: Unfavorable clinical trial results for pipeline products.
- Ongoing: Competition from other companies developing therapies for immune-mediated diseases.
- Potential: Changes in the regulatory landscape that could impact product development and commercialization.
- Ongoing: Dependence on strategic collaborations for development and commercialization.
Growth Opportunities
- Growth opportunity 1: Teplizumab Commercialization: The successful commercialization of teplizumab for the interception of type 1 diabetes represents a significant growth opportunity. The market for T1D therapies is estimated to reach billions of dollars, and a preventative treatment could capture a substantial share. The timeline for this opportunity is near-term, contingent on regulatory approval. Provention Bio's competitive advantage lies in its first-mover status in the T1D interception space.
- Growth opportunity 2: Expansion of Teplizumab Label: Expanding the label for teplizumab to include a broader range of at-risk individuals or earlier stages of T1D could significantly increase its market potential. This would require further clinical trials and regulatory approvals, but the potential return on investment is substantial. The timeline for this opportunity is medium-term, dependent on clinical trial outcomes. Success here would solidify Provention Bio's leadership in T1D prevention.
- Growth opportunity 3: Development of PRV-101 (CVB Vaccine): The development and commercialization of PRV-101, a Coxsackievirus B (CVB) vaccine, represents another significant growth opportunity. CVB infections are linked to the onset of T1D, and a preventative vaccine could reduce the incidence of the disease. The timeline for this opportunity is medium-term, as the vaccine is still in development. Provention Bio's competitive advantage lies in its focus on the root causes of T1D.
- Growth opportunity 4: Advancement of PRV-3279 for Lupus: Advancing PRV-3279 for the treatment of lupus presents a valuable growth avenue. Lupus is a chronic autoimmune disease with a significant unmet need for effective therapies. The timeline for this opportunity is medium to long-term, as the drug is currently in Phase Ib clinical trials. Provention Bio's strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical enhances its ability to develop and commercialize PRV-3279 in Greater China.
- Growth opportunity 5: Pipeline Expansion through Strategic Acquisitions: Provention Bio can pursue strategic acquisitions or licensing agreements to expand its pipeline of immune-mediated disease therapies. This could provide access to new technologies, therapeutic targets, and markets. The timeline for this opportunity is ongoing, as the company continuously evaluates potential opportunities. Provention Bio's financial resources and expertise in immune-mediated diseases position it well to execute such transactions.
Opportunities
- Expansion of teplizumab label to include a broader range of at-risk individuals.
- Development and commercialization of PRV-101 (CVB vaccine).
- Advancement of PRV-3279 for the treatment of lupus.
- Strategic acquisitions or licensing agreements to expand pipeline.
Threats
- Failure to obtain regulatory approvals for product candidates.
- Competition from other companies developing therapies for immune-mediated diseases.
- Unfavorable clinical trial results.
- Changes in the regulatory landscape.
Competitive Advantages
- Proprietary technology and intellectual property related to immune-mediated disease interception.
- First-mover advantage in the T1D prevention space with teplizumab.
- Strategic collaborations with established pharmaceutical companies like Amgen.
- Deep understanding of the underlying mechanisms of immune-mediated diseases.
About PRVB
Provention Bio, Inc., founded in 2016 and headquartered in Red Bank, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's core focus is on addressing conditions like type 1 diabetes (T1D), lupus, celiac disease, and Coxsackievirus B (CVB) infections. Provention Bio's lead product candidate is PRV-031 (teplizumab), a monoclonal antibody currently in Phase III clinical trials for the interception of T1D. This innovative therapy aims to delay or prevent the onset of clinical T1D in at-risk individuals. Beyond teplizumab, Provention Bio's pipeline includes PRV-3279, which has completed Phase Ib clinical trials for the treatment of lupus, and PRV-101, a CVB vaccine designed to prevent acute CVB infections and the subsequent onset of T1D. Additionally, PRV-015 is in Phase IIb clinical trials for the treatment of gluten-free diet non-responding celiac disease. The company strategically collaborates with industry leaders such as Amgen Inc. for PRV-015 and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. for PRV-3279, expanding its development and commercialization capabilities. Provention Bio's commitment to preventative therapies positions it as a key player in the evolving landscape of immune-mediated disease management.
What They Do
- Develop and commercialize therapeutics for immune-mediated diseases.
- Focus on intercepting and preventing the onset of type 1 diabetes (T1D).
- Develop a vaccine for Coxsackievirus B (CVB) infections to prevent T1D.
- Develop treatments for lupus and celiac disease.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Collaborate with other pharmaceutical companies to expand their development and commercialization capabilities.
- Seek regulatory approvals for their products from agencies like the FDA.
Business Model
- Develop and license novel therapeutics for immune-mediated diseases.
- Generate revenue through the sale of approved products, such as teplizumab.
- Collaborate with other pharmaceutical companies to share development costs and commercialization efforts.
- Receive milestone payments and royalties from licensing agreements.
Industry Context
Provention Bio operates within the biotechnology industry, which is characterized by rapid innovation and high growth potential, particularly in the area of immune-mediated diseases. The market for T1D therapies is substantial, driven by the increasing prevalence of the disease and the unmet need for preventative treatments. The competitive landscape includes companies like BLU (Blueprint Medicines), CALT (Calliditas Therapeutics), DCPH (Deciphera Pharmaceuticals), DICE (Dice Therapeutics), and FUSN (Fusion Pharmaceuticals), each focusing on different therapeutic areas. Provention Bio differentiates itself through its focus on intercepting and preventing disease onset, rather than solely treating existing conditions.
Key Customers
- Individuals at risk of developing type 1 diabetes (T1D).
- Patients suffering from lupus and celiac disease.
- Healthcare providers who prescribe and administer Provention Bio's therapies.
- Pharmaceutical companies that collaborate with Provention Bio on development and commercialization.
Financials
Chart & Info
Provention Bio, Inc. (PRVB) stock price: $24.98 (+0.00, +0.00%)
Latest News
-
US Stocks Mostly Higher; Dow Rises 75 Points
benzinga · Mar 13, 2023
-
Earnings Scheduled For August 4, 2022
benzinga · Aug 4, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
· May 11, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PRVB.
Price Targets
Wall Street price target analysis for PRVB.
MoonshotScore
What does this score mean?
The MoonshotScore rates PRVB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
PRVB Healthcare Stock FAQ
What does Provention Bio, Inc. do?
Provention Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to intercept and prevent immune-mediated diseases. Their primary focus is on type 1 diabetes (T1D), with their lead product candidate, teplizumab, aimed at delaying or preventing the onset of clinical T1D in at-risk individuals. In addition to T1D, Provention Bio is also developing therapies for lupus, celiac disease, and Coxsackievirus B (CVB) infections. The company operates through strategic collaborations and internal research and development to advance its pipeline of innovative therapies.
Is PRVB stock worth researching?
Evaluating PRVB stock requires careful consideration of its potential and risks. The company's focus on preventative therapies for immune-mediated diseases, particularly T1D, presents a significant market opportunity. The potential approval and commercialization of teplizumab could drive substantial revenue growth. However, as a clinical-stage company, PRVB is subject to regulatory and clinical trial risks. While the gross margin is high, the negative profit margin reflects ongoing R&D expenses. Investors should weigh the potential for future growth against the inherent risks of investing in a biotechnology company with no currently marketed products.
What are the main risks for PRVB?
The main risks for Provention Bio include the potential failure to obtain regulatory approvals for its product candidates, particularly teplizumab. Unfavorable clinical trial results for pipeline products could also significantly impact the company's value. Competition from other companies developing therapies for immune-mediated diseases poses a threat to market share. Changes in the regulatory landscape could affect product development and commercialization. Additionally, Provention Bio's dependence on strategic collaborations exposes it to risks associated with partner performance and relationship management. These risks are inherent in the biotechnology industry and require careful monitoring.
What are the key factors to evaluate for PRVB?
Provention Bio, Inc. (PRVB) currently holds an AI score of 68/100, indicating moderate score. Key strength: Focus on preventative therapies for immune-mediated diseases.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for teplizumab or other product candidates.. This is not financial advice.
How frequently does PRVB data refresh on this page?
PRVB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PRVB's recent stock price performance?
Recent price movement in Provention Bio, Inc. (PRVB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on preventative therapies for immune-mediated diseases.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PRVB overvalued or undervalued right now?
Determining whether Provention Bio, Inc. (PRVB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PRVB?
Before investing in Provention Bio, Inc. (PRVB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update, financial metrics may not reflect the most recent market conditions.
- Analysis based on available information as of 2026-02-08.